Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00377624 · ClinicalTrials.gov registry record · Phase 3
HUPS: Hyalgan Use in Painful Shoulder
A Phase 3 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 3
- Development phase
- 602
- Enrollment target
NCT00377624: Completed Phase 3 study, sponsored by Sanofi.
NCT00377624 is a Phase 3 study that has completed, run by Sanofi. The registered enrollment target is 602 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (22% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00377624, a Phase 3 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 602 participants
- Enrollment target
Study Summary
Three-arm, parallel, double-blind, masked observer, randomized, PB-Saline controlled clinical trial. In order to avoid problems in the interpretation of the final results due to disparate enrollment from various centers, the number of patients enrolled per site will be the same per site. Study patients will be randomized to receive either 20 mg sodium hyaluronate, 3 i.a. sodium hyaluronate injections, followed by 2 PBSaline mock i.a. injections or 5 i.a. PB-Saline control injections. One investigator will administer the injection and the joint assessor will be blinded to the study. The anterior or posterior approach for the shoulder injection will be used.
Interventions
- DRUG sodium hyaluronate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 602 participants |
| Start Date | 2002-01 |
| Est. Completion | 2004-09 |
| Phase | Phase 3 |
What the finished NCT00377624 record still lists
NCT00377624 is an interventional study that assigns participants to a tested intervention. The registered 602 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (22% lower).
The record links to 0 conditions, and to 1 intervention - of which sodium hyaluronate is the first listed.
NCT00377624 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00377624 about?
NCT00377624 is a clinical study titled "HUPS: Hyalgan Use in Painful Shoulder". Three-arm, parallel, double-blind, masked observer, randomized, PB-Saline controlled clinical trial. In order to avoid problems in the interpretation of the final results due to disparate enrollment from various centers, the number of patients enrolled per site will be the same per site. Study patie...
What is the current status of trial NCT00377624?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 602 participants. The study started on 2002-01. Estimated completion is 2004-09.
What interventions are being tested in trial NCT00377624?
The interventions under investigation include: sodium hyaluronate (DRUG).
Who is sponsoring clinical trial NCT00377624?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00377624's enrollment target sits among peer trials
602 607th of 2000 higher than 1,393 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03849443 · 604 participants · Early Phase 1
Single Versus Multi-Dose Oral and Intravenous Tranexamic Acid Patients at High Risk for Blood Transfusion After Spine Surgery
- NCT05238922 · 604 participants · Phase 1
Study of INCB123667 in Subjects With Advanced Solid Tumors
- NCT06040541 · 604 participants · Phase 1
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
- NCT00004317 · 600 participants · Phase 4
Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia